MENU
$27.95
SIZE
QUANTITY

AVAILABLE AT

Available at these stores well.ca wholefoods Natural food Healthy Planet

NAC (N-ACETYL-L-CYSTEINE)

The Ultimate Antioxidant for Liver, Respiratory and Cardiovascular Support

N-acetyl-L-cysteine (NAC) is a sulfur-containing precursor of the amino acid L-cysteine and the antioxidant glutathione.

AVAILABLE IN

About NAC (N-ACETYL-L-CYSTEINE)

As an antioxidant, NAC protects cells from damage caused by the excessive oxidative stress that results from inflammation, chronic disease, prolonged strenuous exercise, pollution exposure and generalized stress.

NAC also minimizes the liver damage caused by the overuse of certain pharmaceutical drugs like acetaminophen and the acute exposures to environmental chemicals. In fact it’s been administered in hospital emergency departments for this purpose for decades. NAC replenishes the body’s own antioxidant, glutathione. However, NAC is more useable by the body than supplementary glutathione, which typically cannot be absorbed intact when ingested.

 Another great benefit of NAC is respiratory support. It has the ability to reduce the viscosity of mucus and stimulate the clearing of mucus from the airways. This makes NAC a valuable component of any respiratory symptom-management program where congestion occurs. Additionally, NAC protects the lungs from the damaging effects of inhaled pollutants--like smoke, and chemical fumes.

NAC also supports heart health by normalizing homocysteine and lipoprotein(a) levels--- two biomarkers associated with cardiovascular disease when they are elevated.

 Pure Lab’s NAC provides 600 milligrams of N-acetyl-L-cysteine per capsule. We add no other medicinal ingredients, enabling you to achieve your desired dose in fewer capsules. You’ll know our product is fresh as soon as you open the bottle, as it will have a characteristic sulfurous odour—compliments of fully-intact cysteine.

Ingredients

Research

Allen J, Bradley RD. Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. J Altern Complement Med. 2011;17(9):827-833.

Conrad C, Lymp J, Thompson V, et al. Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. J Cyst Fibros. 2015;14(2):219-227.

De Flora S, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J. 1997;10(7):1535-1541.

Dekhuijzen PN, van Beurden WJ. The role for N-acetylcysteine in the management of COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(2):99-106.

Dodd S, Dean O, Copolov DL, Malhi GS, Berk M. N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther. 2008;8(12):1955-1962.

Gavish D, Breslow JL. Lipoprotein(a) reduction by N-aetylcysteineLancet 1991; 337:203-204.

Heard KJ. Acetylcysteine for acetaminophen poisoning. N Engl J Med. 2008;359(3):285-292.

Jeremias A, Soodini G, Gelfand E, et al. Effects of N-acetyl-cysteine on endothelial function and inflammation in patients with type 2 diabetes mellitusHeart Int. 2009;4(1):e7.

Khoshbaten M, Aliasgarzadeh A, Masnadi K, et al. N-acetylcysteine improves liver function in patients with non-alcoholic Fatty liver disease. Hepat Mon. 2010;10(1):12-16.

Lee PH, Hong J, Jang AS. N-acetylcysteine decreases airway inflammation and responsiveness in asthma by modulating claudin 18 expression. Korean J Intern Med. 2020;35(5):1229-1237.

Millea PJ. N-acetylcysteine: multiple clinical applications. Am Fam Physician. 2009;80(3):265-269.

Stey C, Steurer J, Bachmann S, Medici TC, Tramèr MR. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J. 2000;16(2):253-262.

van Zandwijk N. N-acetylcysteine for lung cancer preventionChest. 1995 May;107(5):1437-41.

Yilmaz H, Sahin S, Sayar N, et al. Effects of folic acid and N-acetylcysteine on plasma homocysteine levels and endothelial function in patients with coronary artery disease. Acta Cardiol. 2007;62(6):579-585.

We Want to Hear From You!

Please leave us feedback on your experience with our products. We make them for you.

WHAT'S HAPPENING AT PLV